Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention

Vranckx, 2018, Lancet, 392, 940, 10.1016/S0140-6736(18)31858-0 Watanabe, 2019, Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial, JAMA, 321, 2414, 10.1001/jama.2019.8145 Hahn, 2019, Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial, JAMA, 321, 2428, 10.1001/jama.2019.8146 Mehran, 2019, Ticagrelor with or without aspirin in high-risk patients after PCI, N Engl J Med, 381, 2032, 10.1056/NEJMoa1908419 Kim, 2020, Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial, JAMA, 323, 2407, 10.1001/jama.2020.7580 Capodanno, 2022, P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention, Nat Rev Cardiol, 19, 829, 10.1038/s41569-022-00725-6 Collet, 2021, 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, Eur Heart J, 42, 1289, 10.1093/eurheartj/ehaa575 Levine, 2016, 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 68, 1082, 10.1016/j.jacc.2016.03.513 Nakamura, 2020, JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease, Circ J, 84, 831, 10.1253/circj.CJ-19-1109 Valgimigli, 2021, P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials, BMJ, 373, n1332, 10.1136/bmj.n1332 Kumbhani, 2015, State-of-the-art: hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus, Curr Cardiovasc Risk Rep, 9, 4, 10.1007/s12170-014-0430-5 Capodanno, 2020, Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus, Circulation, 142, 2172, 10.1161/CIRCULATIONAHA.120.045465 Angiolillo, 2014, Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease, J Am Coll Cardiol, 64, 1005, 10.1016/j.jacc.2014.06.1170 Erlinge, 2008, Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo, J Am Coll Cardiol, 52, 1968, 10.1016/j.jacc.2008.07.068 Chouchene, 2018, Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19∗2 genotype?, Eur J Clin Pharmacol, 74, 1567, 10.1007/s00228-018-2530-5 Angiolillo, 2006, Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment, J Am Coll Cardiol, 48, 298, 10.1016/j.jacc.2006.03.038 Levine, 2014, Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI, Nat Rev Cardiol, 11, 597, 10.1038/nrcardio.2014.104 Watanabe, 2022, Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial, JAMA Cardiol, 7, 407, 10.1001/jamacardio.2021.5244 Obayashi, 2022, Clopidogrel monotherapy after 1-month dual antiplatelet therapy in percutaneous coronary intervention: from the STOPDAPT-2 Total Cohort, Circ Cardiovasc Interv, 15, 10.1161/CIRCINTERVENTIONS.122.012004 Rao, 1988, Thrombolysis In Myocardial Infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase, J Am Coll Cardiol, 11, 1, 10.1016/0735-1097(88)90158-1 Cutlip, 2007, Clinical end points in coronary stent trials: a case for standardized definitions, Circulation, 115, 2344, 10.1161/CIRCULATIONAHA.106.685313 Urban, 2019, Defining high bleeding risk in patients undergoing percutaneous coronary intervention, Circulation, 140, 240, 10.1161/CIRCULATIONAHA.119.040167 Chichareon, 2020, Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: pre-specified subgroup analysis from the randomized GLOBAL LEADERS study, Atherosclerosis, 295, 45, 10.1016/j.atherosclerosis.2020.01.002 Angiolillo, 2020, Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention, J Am Coll Cardiol, 75, 2403, 10.1016/j.jacc.2020.03.008 Gravel, 2019, Modulation of CYP450 activities in patients with type 2 diabetes, Clin Pharmacol Ther, 106, 1280, 10.1002/cpt.1496 Franchi, 2019, Pharmacodynamic effects of vorapaxar in patients with and without diabetes mellitus: results of the OPTIMUS-5 study, J Am Coll Cardiol Basic Trans Science, 4, 763 Angiolillo, 2011, A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing Anti-Platelet Therapy in Diabetes Mellitus (OPTIMUS)-3 trial, Eur Heart J, 32, 838, 10.1093/eurheartj/ehq494 Franchi, 2020, Circulation, 142, 1500, 10.1161/CIRCULATIONAHA.120.048770 Watanabe, 2021, Cardiovasc Interv Ther, 36, 403, 10.1007/s12928-020-00719-6 Ertugrul, 2010, Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus, J Clin Endocrinol Metab, 95, 2897, 10.1210/jc.2009-2392 Cohen, 2008, Aspirin resistance associated with HbA1c and obesity in diabetic patients, J Diabetes Complications, 22, 224, 10.1016/j.jdiacomp.2007.05.002 Price, 2011, Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial, JAMA, 305, 1097, 10.1001/jama.2011.290 Pereira, 2020, Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial, JAMA, 324, 761, 10.1001/jama.2020.12443 Wang, 2021, Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA, N Engl J Med, 385, 2520, 10.1056/NEJMoa2111749 Koo, 2021, Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial, Lancet, 397, 2487, 10.1016/S0140-6736(21)01063-1 Angiolillo, 2020, Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score, J Am Coll Cardiol Intv, 13, 606, 10.1016/j.jcin.2020.01.226 Kanenawa, 2021, Patient selection and clinical outcomes in the STOPDAPT-2 trial: an all-comer single-center registry during the enrollment period of the STOPDAPT-2 randomized controlled trial, Circ Cardiovasc Interv, 14, 10.1161/CIRCINTERVENTIONS.120.010007 Inohara, 2020, Comparative trends in percutaneous coronary intervention in Japan and the United States, 2013 to 2017, J Am Coll Cardiol, 76, 1328, 10.1016/j.jacc.2020.07.037